Kangmei Pharmaceutical (stock code: 600518.SH) has revoked other risk warnings on its stocks.

According to the regulations of the Shanghai Stock Exchange listing rules, Kangmei Pharmaceutical (stock code: 600518.SH), the ST listed company, will be suspended for one day on July 3, 2024, and will resume trading on July 4, 2024 with the cancellation of other risk warnings. After the cancellation of other risk warnings, the company's stock will be traded on the exchange rather than on the risk warning board, and the daily limit of stock price fluctuations will be changed from 5% to 10%. The company's stock abbreviation will be changed from "ST Kangmei" to "Kangmei Pharmaceutical", and the stock code will remain as "600518".

Gelonghui FinanceJul 2 06:07 ET

Kangmei Pharmaceutical (600518.SH): The company's stocks apply for the revocation of other risk warnings.

Kangmei Pharmaceutical (600518.SH) announced on June 26 that as of the disclosure date of the announcement, the corresponding situation of the "other risk warnings" triggered by the audit report with a negative opinion on its internal controls in 2020 has been eliminated. The Bohai International Trust Co., Ltd. and Kangmei (Bozhou) Huatuo International Chinese Medicine City Co., Ltd., Bozhou Xincheng World Trading Co., Ltd. and other financial loan contract disputes (referred to as the "Bohai Trust Case") have been adjudicated and entered the implementation process. The company has taken measures to protect its legitimate rights and interests in accordance with the law, and the company's profitability continues to improve.

Gelonghui FinanceJun 26 07:01 ET

Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 57%, While Private Companies Hold 30%

Key Insights Kangmei Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 43% of

Simply Wall StJun 24 21:15 ET

Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price

Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) price-to-sales (or "P/S") ratio of 5.5x may not look like an appealing investment opportunity when you consider close to half the companies in the Phar

Simply Wall StMay 13 18:26 ET

Kangmei Pharmaceutical Logs Profit in Q1

Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 7.5 million yuan, or 0.001 yuan per share, in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang

MT NewswiresApr 30 06:09 ET

ST Kangmei (600518.SH) announced first-quarter results, net profit of 7.4713 million yuan

ST Kangmei (600518.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...

Zhitong FinanceApr 29 05:43 ET